Labiotech.eu

News and Trends 18 Aug 2015

Fresh money for Kuros to Speed up Bone repair

Kuros Biosurgery raised CHF15 million (€13.8M) to bring its late stage bone-repairing agents to the market. A second financing round is already planned for later this year. Bones can suffer a lot during surgeries, sports or severe accidents. To accelerate its healing, Swiss Kuros has established a late stage pipeline of bone-repairing agents. The company was […]

August 18, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Aug 2015

Pfizer uses HiFiBiO’s brand-new technology to discover unique antibodies

French biotech startup HiFiBiO announced today it has achieved a milestone in its research collaboration with American giant Pfizer to develop new antibody therapeutics. The new milestone is triggering an undisclosed payment to HiFiBiO. The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 17 Aug 2015

Genmab’s Bispecific Antibodies Catch Another Big Fish

Genmab, the Danish company developing the DuoBody technology platform to create and develop bispecific antibody candidates, just signed another licensing agreement with a Big Pharma company. This time, Novo Nordisk has been caught in a potential $502 million (€453m) deal. The DuoBody technology involves three basic steps to generate stable bispecific human IgG1 antibodies. In the first step, […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 17 Aug 2015

What if the Best Coffee could be obtained thanks to Biotechnologies?

French bioengineers Camille Delebecque and Sophie Deterre founded the food Start-up Afineur in New York to revolutionize coffee. You may have heard of the Kopi Luwak or Civet Coffee from Indonesia. If not, it’s a very special coffee and one of the most expensive with prices reaching €550/kg. The raw coffee beans are eaten by Asian Palm […]

August 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Aug 2015

What happened this week? Woodford spent €800m, CRISPR discoverer moves to Berlin, the first Bacteria-made ink…

Encouraging facts for the European Biotech ecosystem this week! Neil Woodford’s mega Biotech fund is gathering new money to pour over the European companies. Definitely good news for the financing of companies in Europe, which still lags behind the US. Another interesting fact is that one of the co-discoverer of CRISPRs, the biggest discovery of the century, […]

August 16, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 Aug 2015

The Sky is the Limit: Novo Nordisk continues to rise

The world’s leading insulin supplier, Novo Nordisk, turns in a superb performance in the first six months of 2015. Sales revenues increased, two IIIa trials were successfully completed and two new treatments are now available on the huge diabetes market of the US. We visited Denmark for our last Labiotech tour. We knew Novo was […]

August 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

Stem cell research grows and grows in Europe! For the first time ever, researchers succeded to effectively grow a large number of muscle cells derived from pluripotent stem cells! Researchers from six European countries are participating in the PluriMes project to give a cutting edge to the European stem cell research. Launched in February 2014, […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

Roche’s €382M Acquisition to Expand its Fight against Drug-Resistant Bacteria

The biggest biotech company worldwide has just become even bigger: Roche acquired the Californian GeneWEAVE BioSciences, a privately held company that developed a cool technology to diagnose drug-resistant bacteria. For the integration, Roche shells out $190M (€171M) upfront and up to $235M (€211M) product-related milestones. GeneWEAVE is an American company that developed a technology which is […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in Europe. And Woodford just announced he invested over 75% of the total money he raised, so over €800M. Let’s have a look at where the money went into. Neil Woodford is a legendary British Biotech investor who opened a new […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche just dropped a first-generation antibody-based treatment preventing cancer cells from proliferating. Interestingly enough, the partner of the collaboration, Wilex’ subsidiary Heidelberg Pharma, stated the research “progressed well, on schedule, and in a mutually satisfactory manner”. What happened? Heidelberg Pharma is a German company that discovers new drugs using its platform technology for antibody drug […]

August 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

French, young and brilliant, Emmanuelle Charpentier will now be working as a director at the Max Planck Institute for Infection Biology in Berlin! Emmanuelle Charpentier is labeled one of the most influential scientists by the Time magazine when she discovered THE new technology of the century: CRISPR-Cas9. Among numerous honors, she won the $3M Breakthrough Prizes […]

August 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

A Tale of Love for UniQure and Bristol-Myers Squibb

In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure’s gene therapy platform to treat cardiovascular diseases. Everything seems to work out fine as BMS paid $53M (€47M) for three new targets and additional shares to own nearly 10% of the company. UniQure is a Dutch pioneer in the field of gene therapy. It […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Fresh money for Kuros to Speed up Bone repair

Pfizer uses HiFiBiO’s brand-new technology to discover unique antibodies

Genmab’s Bispecific Antibodies Catch Another Big Fish

What if the Best Coffee could be obtained thanks to Biotechnologies?

What happened this week? Woodford spent €800m, CRISPR discoverer moves to Berlin, the first Bacteria-made ink…

The Sky is the Limit: Novo Nordisk continues to rise

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

Roche’s €382M Acquisition to Expand its Fight against Drug-Resistant Bacteria

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Roche abandons Wilex to Make Way for Immuno-Oncology

Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

A Tale of Love for UniQure and Bristol-Myers Squibb

Subscribe to our newsletter to get the latest biotech news!